Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 17/20 | 0.72 |
| ▸ | KLK1 | P06870 | 1/20 | 0.66 |
| ▸ | GPR183 | P32249 | 1/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8175554 | 0.87 | F10 (0.74) | F10KLK1OPRM1HRH1HRH4 | |
| SCHEMBL27670602 | 0.87 | F10 (0.72) | F10KLK1GPR183OPRM1 | |
| SCHEMBL5090935 | 0.84 | F10 (0.70) | F10KLK1OPRM1 | |
| SCHEMBL5196283 | 0.84 | F10 (0.71) | F10KLK1 | |
| SCHEMBL6801431 | 0.83 | F10 (1.00) | F10KLK1 | |
| SCHEMBL17938678 | 0.83 | GPR183 (0.82) | GPR183HRH1HRH4HRH3 | |
| SCHEMBL1302499 | 0.82 | F10 (0.68) | F10KLK1 | |
| SCHEMBL6807886 | 0.82 | F10 (0.75) | F10KLK1 | |
| SCHEMBL6734799 | 0.82 | F10 (0.69) | F10KLK1OPRM1HRH1HRH4 | |
| SCHEMBL6730422 | 0.81 | F10 (0.74) | F10KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7419979-B2 | Derivatives of 6-{4-[4-(1H-indole-2-sulphonyl)-piperazin-1-carbonyl-phenyl]}pyradizin-3-one | ASTRAZENECA AB (SE) | 2008-09-02 | — | — | US | disclosed |
| US-20070135441-A1 | New derivatives of 6-{4-[4-(1h-indole-2-sulphonyl)-piperazin-1-carbonyl-phenyl]}pyradizin-3-one | ASTRAZENECA AB (SE) | 2007-06-14 | — | — | US | disclosed |
| EP-1706120-A1 | NEW DERIVATIVES OF 6- 4 4 - 1 H - INDOLE-2-SULPHONYL)-PIPERA ZIN-1-CARBONYL-PHENYL PYRADIZIN-3-ONE | AstraZeneca AB (SE) | 2006-10-04 | — | — | EP | disclosed |
| WO-2005065688-A1 | NEW DERIVATIVES OF 6-4{4-[1H-INDOLE-2-SULPHONYL)-PIPERAZIN-1-CARBONYL-PHENYL]}PYRADIZIN-3-ONE | ASTRAZENECA AB (SE) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135441-A1 | New derivatives of 6-{4-[4-(1h-indole-2-sulphonyl)-piperazin-1-carbonyl-phenyl]}pyradizin-3-one | HTR7, TRPC7, HRH4 | F10 803/4885KLK1 3405/4885GPR183 3315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.